Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Titomic wins US$5 million U.S. Air Force contract for cold spray system at Tinker AFB

Titomic wins US$5 million U.S. Air Force contract for cold spray system at Tinker AFB

ReutersReuters2026/09/15 01:15
  • Titomic won a US$ 5 million U.S. Air Force contract to supply and commission a next-generation high-pressure cold spray system.
  • System will be installed at Tinker Air Force Base in Oklahoma City, targeting depot-level sustainment manufacturing and component repair.
  • Delivery is scheduled for 3Q 2027, with installation timing subject to site coordination and approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Titomic Ltd. published the original content used to generate this news brief via CNW (Ref. ID: 202609142114CANADANWCANADAPR_C1261) on September 15, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage